MDCG 2023-3: new version published

Guideline MDCG 2023-3 Rev.2 is an important update in the landscape of the regulation on medical device and in vitro diagnostics.
Published in January 2025, this updated version outlines more clearly terms and concepts related to vigilance, offering a reference point that is essential for manufacturers, competent authorities and other economic operators.
The goal of the MDCG 2023-3 Rev.2
The main goal is to ensure a uniform and harmonised regulation on MDR (2017/745) and IVDR (2017/746) all over the European Union.
Compared to the previous version, Rev.2 introduces some changes, especially regarding the definition and the classification of “incident” and “serious incident”.
These terms were further clarified to delete any interpretative ambiguity. The guideline includes a detailed description of the circumstances distinguishing a serious incident from one that is less relevant, offering practical examples to help operators better understand the reporting criteria.
Another crucial aspect addressed in the new version is the role of EUDAMED, the European medical device database.
A centralised collection
The document examines in depth how this tool should be used for incident reporting and monitoring, highlighting the importance of a centralised and standardised collection of information.
This contributes not only to a greater transparency, but also to a global improvement of patients’ safety, thanks to a more effective management of data and reports.
Besides, Rev.2 also provided more detailed information on the technical requirements and on the best practice for vigilance management.
This is particularly useful for manufacturers, that in this way can comply more specifically with the European legislation, reducing any risk of non conformity.
The new guidelines reflect the European Union commitment in ensuring that the patients’ safety is always at the core of the medical device regulation.
Overall, guideline MDCG 2023-3 Rev.2 marks a step forward towards more clarity and consistency in the application of the MDR and IVDR.
Not only do the changes brought about simplify the understanding of the vigilance requirements, but they also enhance the trust in the European regulatory system, ensuring that medical devices put on the market are safe and effective for patients.
Our consultancy on medical device vigilance
Di Renzo Regulatory Affairs offers full support in the sector of device vigilance, making available for their clients a wide range of specialised services.
These include taking on the role of Vigilance Responsible Person either in Italy or in Europe, as appointed by the manufacturers, or the role of local contact point in the cases where manufacturers wish to manage vigilance activities themselves.
Moreover, we take care of the preparation and transmission of notifications, corrective actions and safety notices to the Competent Authorities, also ensuring support for any request from the CAs.
We assist either manufacturers or their authorised representatives during investigations on incidents contacting, for instance, any reporters for further information, or carrying out specific research in the scientific literature or specialized safety databases.
We provide our Clients with continuous updates on the evolution of the European and national regulations for this sector and, on request, we organise training sessions for the company staff.
We also cooperate with manufacturers to implement, update and manage the post-marketing surveillance and vigilance system, by drafting specific Standard Operating Procedures, collecting feedback information from the market and clinical data, and continuously updating all required technical documents (e.g. post-marketing surveillance plans and reports, PSURs, PMCF plans and reports, clinical assessment and risk management plans and reports).
Do you need assistance navigating the complex regulatory landscape of medical devices? Rely on our expertise: we offer tailored regulatory consultancy to ensure full compliance with European and international regulations. 📞 Contact us today for a personalized consultation and bring your devices to market with total confidence!
Previous Post
Next Post